Correction to: Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases
Clin Pharmacokinet
.
2022 Oct;61(10):1475-1476.
doi: 10.1007/s40262-022-01166-7.
Authors
Ying Fei Li
1
,
Francois Pierre Combes
2
,
Matthias Hoch
3
,
Sebastien Lorenzo
4
,
Sherwin K B Sy
2
,
Yu-Yun Ho
2
Affiliations
1
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. ying_fei.li@novartis.com.
2
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
3
Novartis Institute for Biomedical Research, Basel, Switzerland.
4
Novartis Pharmaceuticals Corporation, Basel, Switzerland.
PMID:
35976571
DOI:
10.1007/s40262-022-01166-7
No abstract available
Publication types
Published Erratum